| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | semagacestat | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | AMG-706 | FIMM | pan-cancer | AAC | -0.021 | 0.9 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |